LA JOLLA PHARMACEUTICAL COMPANY (NASDAQ:LJPC) Files An 8-K Entry into a Material Definitive Agreement

LA JOLLA PHARMACEUTICAL COMPANY (NASDAQ:LJPC) Files An 8-K Entry into a Material Definitive Agreement

Story continues below

LA JOLLA PHARMACEUTICAL CO Exhibit
EX-2.1 2 d949145dex21.htm EX-2.1 EX-2.1 Exhibit 2.1 EXECUTION VERSION       AGREEMENT AND PLAN OF MERGER among: LA JOLLA PHARMACEUTICAL COMPANY,…
To view the full exhibit click here

About LA JOLLA PHARMACEUTICAL COMPANY (NASDAQ:LJPC)

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. It is engaged in the research, development and commercialization of its technologies and drug candidates for pharmaceutical products. Its product candidates in development include LJPC-501, LJPC-401, LJPC-30Sa and LJPC-30Sb. The Company is developing LJPC-501 for the treatment of catecholamine-resistant hypotension (CRH). The Company is developing LJPC-401 for the treatment of iron overload, which occurs as a result of diseases, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. It is developing LJPC-30Sa and LJPC-30Sb not only for the treatment of serious bacterial infections but also for the potential treatment of rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.

An ad to help with our costs